€322.50 resistance breached: Virbac stock continues its upward trend
The veterinary laboratory based in Carros extends its recovery in a Paris market oriented upwards. The security ranks among the strongest gainers in the SBF 120 and has just crossed a technical threshold that had been resisting it for several weeks.
A resistance at €322.50 breached during the session, following a week of rebound
The Virbac stock gains 2.21% to €324 during the session, while the SBF 120 advances by 0.28%. The security has breached upwards its resistance of €322.50 and is holding above it. This movement extends a gain of 5.54% over seven days, following the very brief breach of the €302 support in early October.
The price is now above its 20-day moving average (spread of +4.36%) and its 50-day moving average (+1.10%), but remains below the 200-day moving average at €343.71, a spread of 5.73%. The RSI at 54 is neutral: it signals neither overbought nor exhaustion following this series of positive sessions.
2026 targets confirmed at the upper end and a meeting scheduled for October 19
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During the publication of first-half 2026 results, on September 17, the group reported organic growth of 7.4% and confirmed its annual targets, now at the upper end of its range. The security had fallen more than 5% the following day, which leaves a gap to close before the 200-day moving average. The €1 billion share buyback program announced on June 9, 2026 is part of the context of the security. The next financial meeting is the publication of third-quarter 2026 revenue, expected on October 19.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
